Biochips Market by Type, Fabrication Technology, Application, End-User

List of Tables

[182 Pages Report] The Biochips Market size was estimated at USD 20.29 billion in 2023 and expected to reach USD 24.10 billion in 2024, at a CAGR 19.44% to reach USD 70.40 billion by 2030.

A biochip is a collection of microscopic test sites arranged on a solid substrate that allows many tests to be performed simultaneously to achieve higher throughput and speed. Biochips are used in various fields, including medical and pharmaceutical research, disease diagnostics, drug discovery, agricultural science, and environmental protection. The growing prevalence of life-threatening disorders and the rise in the geriatric population are driving the growth of the biochips market. Moreover, advancements in the biotechnology sector along with the growing demand for personalized adoption owing to increased adoption of biochips. However, the high cost of biochip products, coupled with the requirement of high initial investment, hampers the market growth. Additionally, unfavorable reimbursement scenarios and a lack of awareness of this technology in developing countries inhibit the market's full potential. Furthermore, the continuous developments in the field, such as nano-biochips, are creating promising opportunities for venturing businesses and potential pioneers in the industry. Exploring advancements in microarray technology, improving data quality via noise removal, and enhancing biochip functional capabilities through miniaturization are a few such avenues.

KEY MARKET STATISTICS
Base Year [2023]	USD 20.29 billion
Estimated Year [2024]	USD 24.10 billion
Forecast Year [2030]	USD 70.40 billion
CAGR (%)	19.44%

Regional Insights

The United States and Canada hold a significant share of the biochip market in the Americas; with heavy investments in the healthcare sector, especially in personalized medicine and genetic research, an increasing scope for biochip usage is evident. The Americas, being the hub of significant biochip manufacturers, holds numerous patents depicting its leadership in biochip technology. In the EMEA region, EU countries significantly contribute to the biochips market due to advanced medical facilities, heightened healthcare awareness, and substantial healthcare budgets. Additionally, the EU has stimulated investments in the Biotech industry, empowering research and innovation in the biochip field. This support includes funding for numerous projects and patent rights for biochip technology. In contrast, the Middle East and Africa, while rising on the economic front, are yet to fully embrace the potential of the biochip market. However, there is a growing awareness about the advantages of biochips in effective disease diagnosis and personalized medicine, indicating prospective growth in the region. The Asia Pacific region, particularly China, Japan, and India, has shown an increasing demand for biochips due to the rising chronic diseases prevalence and the robust growth of the pharmaceutical sector. Significant investment has been made in healthcare technologies, specifically in biochips.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Biochips Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers
- Increasing incidences of life-threatening disorder and rise in geriatric population
- Growing demand of personalized medicine for the treatment of cancer
- Increasing Demand for Point-of-care Testing

Market Restraints
- High cost associated with the manufacturing of biochips products

Market Opportunities
- Ongoing advancements in field of genomics and proteomics
- Rising investments in the field of biotechnology from private & public sectors

Market Challenges
- Stringent regulations associated with the manufacturing and implementation of biochips

Market Segmentation Analysis
- Type: Consumer preference for lab-on-a-chip for point-of-care diagnostics as they provide quick and accurate results
- Fabrication Technology: Extensive use of microfluidics for point-of-care diagnostics for pathogen detection
- Application: Significant role of biochips in drug discovery utilized for compound identification and target validation
- End-User: Growing preference for biochips by biotechnology & pharmaceutical companies for drug discovery and personalized medicine

Market Disruption Analysis
Porter's Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Biochips Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Biochips Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Archer's First-Generation Biochip gFET Design Validated by Joint Fabrication with a Foundry Partner

Archer Materials Limited, a semiconductor company that manufactures Biochip graphene field effect transistors, has successfully validated its first-generation gFET design through a Multi-Project Wafer obtained from an external German foundry partner. This collaboration marks the first joint fabrication between Archer and an external foundry partner, as the final fabrication processes were conducted in-house by the Company in Australia. The gFETs produced by the MPW have been proven to function as expected, including the demonstration of liquidgating, and are compatible with the Archer Biochip system platform. [Published On: 2023-11-09]

Opteev Files Patent for New Multiplex Biochip

Opteev Technologies has recently filed a patent for a groundbreaking multiplex biochip. This innovative polymer-based biochip has the capability to rapidly and accurately detect various respiratory pathogens like Flu, SARS-CoV-2, and RSV. With a remarkable accuracy rate of 99.49%, this biochip can detect complete viruses in samples such as nasal swabs or saliva within just one minute. The introduction of this technology is expected to bring numerous benefits to healthcare providers. [Published On: 2023-08-01]

Nutcracker Therapeutics Raises $167 Million in Series C Financing to Advance its mRNA Therapeutics and First-of-its-Kind Biochip-based Manufacturing Platform

Nutcracker Therapeutics, a biotech company, has successfully raised USD 167 million in Series C financing. This funding supports the expansion and advancement of Nutcracker's pipeline of mRNA medicines for cancer and the refinement of their RNA manufacturing platform and underlying technology. The company's unique approach combines RNA biochemistry, microfluidic engineering, semiconductor-such as biochips, and a proprietary nanoparticle delivery technology, resulting in an automated and isolated manufacturing pathway. [Published On: 2022-03-14]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Biochips Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Biochips Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ACROBiosystems Inc., Agilent Technologies, Inc., Archer Materials Limited, Bio-Rad Laboratories, Inc., BioMerieux SA, Cellix Ltd. by Randox Laboratories Ltd., Diagnostic Biochips, Inc, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies, Inc., Horiba, Ltd., Illumina, Inc., Innovative Biochips, LLC, LI-COR, Inc., Luminex Corporation by DiaSorin S.p.A., Merck KGaA, Micronit B.V., Nutcracker Therapeutics, Opteev, PerkinElmer Inc., Phalanx Biotech Group Inc. by WIN Semiconductors Corp., QIAGEN N.V., Sphere Fluidics Limited, Standard BioTools Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Biochips Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Arrays
  - Cell Arrays
  - Tissue Arrays

DNA Chips
Lab-On-A-Chip
Protein Chips

Fabrication Technology
- Microarrays
- Microfluidics

Application
- Clinical Diagnostics
- Drug Discovery
- Genomics & Proteomics Source

End-User
- Academic & Research Institutes
- Biotechnology & Pharmaceutical Companies
- Hospitals & Diagnostics Centers

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

Product Code: MRR-430D42AA0CE3

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing incidences of life-threatening disorder and rise in geriatric population
  - 5.1.1.2. Growing demand of personalized medicine for the treatment of cancer
  - 5.1.1.3. Increasing Demand for Point-of-care Testing
- 5.1.2. Restraints
  - 5.1.2.1. High cost associated with the manufacturing of biochips products
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing advancements in field of genomics and proteomics
  - 5.1.3.2. Rising investments in the field of biotechnology from private & public sectors
- 5.1.4. Challenges
  - 5.1.4.1. Stringent regulations associated with the manufacturing and implementation of biochips
5.2. Market Segmentation Analysis
- 5.2.1. Type: Consumer preference for lab-on-a-chip for point-of-care diagnostics as they provide quick and accurate results
- 5.2.2. Fabrication Technology: Extensive use of microfluidics for point-of-care diagnostics for pathogen detection
- 5.2.3. Application: Significant role of biochips in drug discovery utilized for compound identification and target validation
- 5.2.4. End-User: Growing preference for biochips by biotechnology & pharmaceutical companies for drug discovery and personalized medicine
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Biochips Market, by Type

6.1. Introduction
6.2. Arrays
6.3. DNA Chips
6.4. Lab-On-A-Chip
6.5. Protein Chips

7. Biochips Market, by Fabrication Technology

7.1. Introduction
7.2. Microarrays
7.3. Microfluidics

8. Biochips Market, by Application

8.1. Introduction
8.2. Clinical Diagnostics
8.3. Drug Discovery
8.4. Genomics & Proteomics Source

9. Biochips Market, by End-User

9.1. Introduction
9.2. Academic & Research Institutes
9.3. Biotechnology & Pharmaceutical Companies
9.4. Hospitals & Diagnostics Centers

10. Americas Biochips Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Biochips Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Biochips Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Archer's First-Generation Biochip gFET Design Validated by Joint Fabrication with a Foundry Partner
- 13.3.2. Opteev Files Patent for New Multiplex Biochip
- 13.3.3. Nutcracker Therapeutics Raises $167 Million in Series C Financing to Advance its mRNA Therapeutics and First-of-its-Kind Biochip-based Manufacturing Platform
13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio